Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03256799 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations
A Phase 4 study of Cystic Fibrosis, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT03256799 is a Phase 4 study of Cystic Fibrosis that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 1 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03256799, a Phase 4 study of Cystic Fibrosis, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to explore the combination of Ataluren and ivacaftor as a treatment for patients with a specific cystic fibrosis mutation
Conditions Studied
Interventions
- DRUG Ivacaftor/Ataluren
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-03-17 |
| Est. Completion | 2018-02-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03256799
The ClinicalTrials.gov registry entry for NCT03256799 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (99% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Ivacaftor/Ataluren is the first listed.
NCT03256799 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT03256799 about?
NCT03256799 is a clinical study titled "Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations". The purpose of this study is to explore the combination of Ataluren and ivacaftor as a treatment for patients with a specific cystic fibrosis mutation
What is the current status of trial NCT03256799?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2017-03-17. Estimated completion is 2018-02-16.
What conditions does trial NCT03256799 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT03256799?
The interventions under investigation include: Ivacaftor/Ataluren (DRUG).
Who is sponsoring clinical trial NCT03256799?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03256799 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Markers of Osteoporosis in Cystic Fibrosis
RECRUITING · Phase 4
-
BEGIN Novel ImagiNG Biomarkers
RECRUITING · Phase 4
-
Estrogen Supplementation and Bone Health in Women With CF
RECRUITING · Phase 4
-
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
RECRUITING · Phase 4
-
Hyperpolarized Imaging for New Treatments
ACTIVE NOT RECRUITING · Phase 4
-
Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.